- Dec 26, 2018
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...
670
- Dec 16, 2018
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...
557
- Dec 14, 2018
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...
558
- Dec 13, 2018
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...
51
- Dec 13, 2018
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART AllogeneicT-cells with Anti-BCMA CAR Chimeric Antigen Receptor)in the Treatment...
54
- Dec 12, 2018
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. CHINESE STUDY A...
331